Dual Inclusion! Desheng-B (02526) is simultaneously included in the Hang Seng Composite Index and the Hang Seng Biotechnology Index. The company's valuation has significant upside potential.

On August 21, the Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series as of June 30, 2026. DIAGENS-B (02526) has made a significant dual inclusion, being added to both the Hang Seng Composite Index and the Hang Seng Biotechnology Index, becoming the only company included in the Hang Seng Biotechnology Index during this index adjustment. According to the arrangements by the Hang Seng Index Company, the changes to the Hang Seng Biotechnology Index will be implemented after market close on September 11, 2026 (Friday), and will take effect on September 14, 2026 (Monday). Founded in 2016, DIAGENS-B is a technology company that innovates medical diagnostics using AI technology, ranking first in its industry. It has developed the world's first "core universal brain" for the medical imaging fieldthe iMedImage foundational large model, achieving a scale of hundreds of billions of parameters, covering 19 types of medical imaging modalities and 26 clinical specialties. Based on this, it has established the globally leading medical imaging AI "Research and Production Acceleration Platform" iMedLoop, which has accumulated a high-quality medical imaging dataset of 28.95 million entries. In the first half of 2026, the company achieved total operating revenue of 109 million yuan, a year-on-year increase of 21.0%; the gross profit margin remained high at 74.1%. Among this, revenue from model services reached 94.5 million yuan, a substantial year-on-year increase of 101.1%, accounting for 86.9% of total revenue, thus becoming the core engine driving growth. The Hang Seng Biotechnology Index is the core benchmark index of the biotechnology sector in the Hong Kong stock market, focusing on representative innovative biotechnology companies in the Hong Kong stock market. Its constituent stocks include WUXI BIO, BeOne Medicines Ltd., INNOVENT BIO, WuXi AppTec, CSPC PHARMA, and others. This index is also an important reference for many passive index funds and institutional investments, and adjustments to its constituent stocks will directly impact the positioning of related tracking funds. In this quarterly review, DIAGENS-B, as the only new constituent stock, marks the market's high recognition of its technological strength and industry status in the field of AI-enabled healthcare. At the same time, as a rare pure AI4S (AI for Science) target in the Hong Kong stock market, DIAGENS-B has built a complete system from data to models, from models to products, and from products to clinical applications. In the resonance between the wave of the AI4S industry and the significant allocation demand from southbound funds, this dual inclusion in the Hang Seng Index series is expected to significantly enhance the liquidity and trading activity of the companys stock, with substantial potential for valuation increases.